Twi Pharms Drug Patent Portfolio
Twi Pharms owns 2 orange book drugs protected by 2 US patents Given below is the list of Twi Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7674479 | Sustained-release bupropion and bupropion/mecamylamine tablets | 25 Jun, 2027 | Active |
| US5637320 | Controlled absorption naproxen formulation for once-daily administration | 10 Jun, 2014 | Expired |
Latest Legal Activities on Twi Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Twi Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 01 Sep, 2021 | US7674479 |
|
Email Notification
Critical
| 22 Feb, 2018 | US7674479 |
| Mail O.P. Petition Decision | 22 Feb, 2018 | US7674479 |
| Mail-Petition Decision - Granted | 21 Feb, 2018 | US7674479 |
| O.P. Petition Decision | 20 Feb, 2018 | US7674479 |
| Payment of Maintenance Fee under 1.28(c) | 20 Feb, 2018 | US7674479 |
|
Petition Decision - Granted
Critical
| 20 Feb, 2018 | US7674479 |
| Petition Entered | 29 Aug, 2017 | US7674479 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 29 Aug, 2017 | US7674479 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 28 Aug, 2017 | US7674479 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Mar, 2012 | US7674479 |
|
Email Notification
Critical
| 14 Mar, 2012 | US7674479 |
|
Correspondence Address Change
Critical
| 09 Mar, 2012 | US7674479 |
| Post Issue Communication - Certificate of Correction | 13 Aug, 2010 | US7674479 |
|
Recordation of Patent Grant Mailed
Critical
| 09 Mar, 2010 | US7674479 |
Twi Pharms's Drug Patent Litigations
Twi Pharms's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 23, 2008, against patent number US7674479. The petitioner , challenged the validity of this patent, with Horst G. Zerbe et al as the respondent. Click below to track the latest information on how companies are challenging Twi Pharms's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7674479 | December, 2008 |
Decision
(23 Sep, 2009)
| Horst G. Zerbe et al | |
Twi Pharms's Family Patents
Twi Pharms Drug List
Given below is the complete list of Twi Pharms's drugs and the patents protecting them.
1. Forfivo Xl
Forfivo Xl is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7674479 | Sustained-release bupropion and bupropion/mecamylamine tablets |
25 Jun, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Forfivo Xl's drug page
2. Naprelan
Naprelan is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5637320 | Controlled absorption naproxen formulation for once-daily administration |
10 Jun, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Naprelan's drug page